Centogene press release (NASDAQ:CNTG): FY GAAP EPS of -Є1.19.
Revenue of Є47.5M (+12.6% Y/Y).
Significant expansion of gross profit margin from 32% to 42% and ongoing cost control resulted in significant improvement of net results
Both Pharma and Diagnostics segments positioned for strong performance in 2023, guidance of FY2023 total revenue growth between 10% to 15%
The Company expects revenue growth to be between 10 to 15% in FY2023 compared to FY2022.
The Company improved its net loss position by 31% at €31.8 million in FY2022 compared to a net loss of €46.2 million in FY2021.
The Company expects revenue growth to be between 10 to 15% in FY2023 compared to FY2022.
